Alnylam Pharmaceuticals licenses Max Planck patents
Recently founded drug development company Alnylam Pharmaceuticals has licensed various patents in the area of RNA interference (RNAi) from the Max Planck Society, through the latter's tech transfer office Garching Innovation GMBH.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com